Q1 Earnings Estimate for PRCT Issued By Leerink Partnrs

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) – Analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of PROCEPT BioRobotics in a report released on Wednesday, November 5th. Leerink Partnrs analyst M. Kratky anticipates that the company will earn ($0.39) per share for the quarter. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.20) EPS.

Several other equities research analysts have also weighed in on the stock. Piper Sandler reiterated an “overweight” rating and set a $50.00 price objective (down previously from $55.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Wednesday, October 8th. BTIG Research reissued a “neutral” rating on shares of PROCEPT BioRobotics in a report on Tuesday, September 16th. Wells Fargo & Company lowered their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Morgan Stanley dropped their target price on PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 15th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $63.30.

PROCEPT BioRobotics Trading Up 2.0%

PROCEPT BioRobotics stock opened at $31.92 on Thursday. PROCEPT BioRobotics has a 1 year low of $29.78 and a 1 year high of $103.81. The firm’s 50-day moving average is $36.02 and its 200-day moving average is $47.66. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.86 and a current ratio of 8.44. The company has a market cap of $1.78 billion, a P/E ratio of -20.86 and a beta of 0.98.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The firm had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The firm’s revenue was up 42.6% on a year-over-year basis. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS.

Institutional Trading of PROCEPT BioRobotics

Several large investors have recently added to or reduced their stakes in PRCT. Teacher Retirement System of Texas boosted its position in PROCEPT BioRobotics by 16.1% during the 1st quarter. Teacher Retirement System of Texas now owns 11,080 shares of the company’s stock worth $646,000 after acquiring an additional 1,537 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of PROCEPT BioRobotics by 32.5% during the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after purchasing an additional 270 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of PROCEPT BioRobotics by 41.6% during the first quarter. Alps Advisors Inc. now owns 14,828 shares of the company’s stock valued at $864,000 after purchasing an additional 4,353 shares in the last quarter. Arizona State Retirement System lifted its holdings in PROCEPT BioRobotics by 3.2% in the first quarter. Arizona State Retirement System now owns 14,737 shares of the company’s stock worth $859,000 after purchasing an additional 452 shares during the period. Finally, New York State Common Retirement Fund grew its position in PROCEPT BioRobotics by 8.6% in the 1st quarter. New York State Common Retirement Fund now owns 205,495 shares of the company’s stock valued at $11,972,000 after buying an additional 16,341 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).